7Baggers
 Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE)  The Globe and Mail Sat, 15 Nov 2025 17:18:39 GMT
 Candel Therapeutics Broadens Its Clinical Cancer Studies  Kalkine Media Sat, 15 Nov 2025 08:00:00 GMT
 Candel Therapeutics (CADL) Analyst Rating Update: Citigroup Lowe  GuruFocus Fri, 14 Nov 2025 20:40:25 GMT
 Candel pausing development of CAN-2409 in prostate cancer type  Seeking Alpha Fri, 14 Nov 2025 16:47:16 GMT
 candel pausing development of can-2409 in pancreatic cancer type  Seeking Alpha Fri, 14 Nov 2025 16:47:16 GMT
 Candel Therapeutics Advances Cancer Therapies with Strong Q3  TipRanks Fri, 14 Nov 2025 04:42:23 GMT
 Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year  TipRanks Thu, 13 Nov 2025 16:36:33 GMT
 Candel Therapeutics highlights 3Q milestones across cancer immunotherapy pipeline  Proactive financial news Thu, 13 Nov 2025 14:44:00 GMT
 Candel Therapeutics Q3 net loss widens to $11.3 mln  MarketScreener Thu, 13 Nov 2025 14:12:49 GMT
 Candel Therapeutics : Website Candel Corporate Presentation 13Nov2025  MarketScreener Thu, 13 Nov 2025 13:35:13 GMT
 Candel Therapeutics, Inc. SEC 10-Q Report  TradingView Thu, 13 Nov 2025 13:33:00 GMT
 (cadl) and the role of price-sensitive allocations  news.stocktradersdaily.com Wed, 12 Nov 2025 15:10:02 GMT
 candel therapeutics to present phase 3 prostate cancer trial data at sitc  Investing.com Nigeria Wed, 05 Nov 2025 05:22:32 GMT
 candel therapeutics to highlight immunotherapy advances at sitc 2025  Proactive financial news Tue, 04 Nov 2025 14:52:00 GMT
 cadl: stephens & co. initiates coverage with overweight rating |  GuruFocus Tue, 28 Oct 2025 10:38:36 GMT

Candel Therapeutics, Inc.
(NASDAQ:CADL) 

CADL stock logo

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery t...

Founded: 1999
CEO: Paul Peter Tak  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends